Page 88 - Škrgat, Sabina, ed. 2022. Severe Asthma - Basic and Clinical Views. Koper: University of Primorska Press. Severe Asthma Forum, 1
P. 88
26;368(9537):705. doi: 10.1016/S0140- tial as a diagnostic or therapeutictarget.
6736(06)69257-X. Respir Res. 2015 May 17;16(1):57. doi:
severe asthma forum 1: severe asthma - basic and clinical views 9. Lotvall J, Akdis CA, Bacharier LB, et 10.1186/s12931-015-0218-2.
al. Asthma endotypes: a new approach 20. Bentley JK, Chen Q, Hong JY, et al.
to classification of disease entities with- Periostin is required for maximal air-
in the asthma syndrome. J Allergy Clin waysinflammation and hyperrespon-
Immunol. 2011 Feb;127(2):355-60. siveness in mice. J Allergy Clin Immu-
10. Tiotiu A. Biomarkers in asthma: state nol. 2014 Dec;134(6):1433-42.
of the art. Asthma Res Pract. 2018 Dec 21. Takahashi K, Meguro K, Kawashima
21;4:10. doi: 10.1186/s40733-018-0047- H, et al. Serum periostin levels serve as
4. a biomarker for both eosinophilic air-
11. Fajt ML, Wenzel SE. Asthma phe- way inflammation and fixed airflow
notypes and the use of biologic med- limitation in well-controlled asthmatics.
ications in asthma and allergic dis- J Asthma. 2019 Mar;56(3):236-43.
ease: the next steps toward personal- 22. Wagener AH, de Nijs SB, Lutter R et
ized care. J Allergy Clin Immunol. 2015 al. External validation of blood eosin-
Feb;135(2):299-310. ophils, FE(NO) and serum periostin
12. Chung KF. Precision medicine in asth- as surrogates for sputum eosinophils in
ma: linking phenotypes to targeted asthma. Thorax. 2015 Feb;70(2):115-
treatments. Curr Opin Pulm Med. 2018 20.
Jan;24(1):4-10. 23. Berry A, Busse WW. Biomarkers in
13. Kuruvilla ME, Lee FE, Lee GB. Un- asthmatic patients: Has their time come
derstanding Asthma Phenotypes, En- to direct treatment? J Allergy Clin Im-
dotypes, and Mechanisms of Dis- munol. 2016 May;137(5):1317-24.
ease. Clin Rev Allergy Immunol. 2019 24. Wan XC, Woodruff PG. Biomarkers in
Apr;56(2):219-33. Severe Asthma. Immunol Allergy Clin
14. Chung, KF, Israel E, Gibson PG, edi- North Am. 2016 Aug;36(3):547-57.
tors. Severe Asthma. Sheffield: Europe- 25. Rath N, Raje N, Rosenwasser L. Immu-
an Respiratory Society; c2019. (Europe- noglobulin E as a Biomarker in Asthma.
an respiratory monograph; 84). Immunol. Allergy Clin North Am. 2018
15. Berry A, Busse WW. Biomarkers in Nov;38(4):587-97.
asthmatic patients: Has their time come 26. Semprini R, Shortt N, Ebmeier S, et al.
to direct treatment? J Allergy Clin Im- Change in biomarkers of type-2 inflam-
munol. 2016 May;137(5):1317-24. mation following severe exacerbations
16. (16) Wan XC, Woodruff PG. Biomark- of asthma. Thorax. 2019 Jan;74(1):95-
ers in Severe Asthma. Immunol Allergy 8.
Clin North Am. 2016 Aug;36(3):547-57. 27. Fontanella S, Frainay C, Murray CS
17. Pavord ID, Afzalnia S, Menzies-Gow et al. Machine learning to identi-
A, et al. The current and future role of fy pairwise interactions between spe-
biomarkers in type 2 cytokine-mediated cific IgE antibodies and their associ-
asthma management. Clin Exp Allergy. ation with asthma: A cross-section-
2017 Feb;47(2):148-60. al analysis within a population-based
18. Syabbalo N. Biomarkers for Diagnosis birth cohort. PLoSMed. 2018 Nov
and Management of Eosinophilic Asth- 13;15(11):e1002691. doi: 10.1371/jour-
ma. Ann Clin Med Res. 2020;1(1):1003. nal.pmed.1002691.
19. Li W., Gao P, Zhi Y, et al. Perios- 28. Mayo Clinic Laboratories. TEST ID:
tin: Its role in asthma and its poten- IGE [Internet]. [place unknown]: Mayo
6736(06)69257-X. Respir Res. 2015 May 17;16(1):57. doi:
severe asthma forum 1: severe asthma - basic and clinical views 9. Lotvall J, Akdis CA, Bacharier LB, et 10.1186/s12931-015-0218-2.
al. Asthma endotypes: a new approach 20. Bentley JK, Chen Q, Hong JY, et al.
to classification of disease entities with- Periostin is required for maximal air-
in the asthma syndrome. J Allergy Clin waysinflammation and hyperrespon-
Immunol. 2011 Feb;127(2):355-60. siveness in mice. J Allergy Clin Immu-
10. Tiotiu A. Biomarkers in asthma: state nol. 2014 Dec;134(6):1433-42.
of the art. Asthma Res Pract. 2018 Dec 21. Takahashi K, Meguro K, Kawashima
21;4:10. doi: 10.1186/s40733-018-0047- H, et al. Serum periostin levels serve as
4. a biomarker for both eosinophilic air-
11. Fajt ML, Wenzel SE. Asthma phe- way inflammation and fixed airflow
notypes and the use of biologic med- limitation in well-controlled asthmatics.
ications in asthma and allergic dis- J Asthma. 2019 Mar;56(3):236-43.
ease: the next steps toward personal- 22. Wagener AH, de Nijs SB, Lutter R et
ized care. J Allergy Clin Immunol. 2015 al. External validation of blood eosin-
Feb;135(2):299-310. ophils, FE(NO) and serum periostin
12. Chung KF. Precision medicine in asth- as surrogates for sputum eosinophils in
ma: linking phenotypes to targeted asthma. Thorax. 2015 Feb;70(2):115-
treatments. Curr Opin Pulm Med. 2018 20.
Jan;24(1):4-10. 23. Berry A, Busse WW. Biomarkers in
13. Kuruvilla ME, Lee FE, Lee GB. Un- asthmatic patients: Has their time come
derstanding Asthma Phenotypes, En- to direct treatment? J Allergy Clin Im-
dotypes, and Mechanisms of Dis- munol. 2016 May;137(5):1317-24.
ease. Clin Rev Allergy Immunol. 2019 24. Wan XC, Woodruff PG. Biomarkers in
Apr;56(2):219-33. Severe Asthma. Immunol Allergy Clin
14. Chung, KF, Israel E, Gibson PG, edi- North Am. 2016 Aug;36(3):547-57.
tors. Severe Asthma. Sheffield: Europe- 25. Rath N, Raje N, Rosenwasser L. Immu-
an Respiratory Society; c2019. (Europe- noglobulin E as a Biomarker in Asthma.
an respiratory monograph; 84). Immunol. Allergy Clin North Am. 2018
15. Berry A, Busse WW. Biomarkers in Nov;38(4):587-97.
asthmatic patients: Has their time come 26. Semprini R, Shortt N, Ebmeier S, et al.
to direct treatment? J Allergy Clin Im- Change in biomarkers of type-2 inflam-
munol. 2016 May;137(5):1317-24. mation following severe exacerbations
16. (16) Wan XC, Woodruff PG. Biomark- of asthma. Thorax. 2019 Jan;74(1):95-
ers in Severe Asthma. Immunol Allergy 8.
Clin North Am. 2016 Aug;36(3):547-57. 27. Fontanella S, Frainay C, Murray CS
17. Pavord ID, Afzalnia S, Menzies-Gow et al. Machine learning to identi-
A, et al. The current and future role of fy pairwise interactions between spe-
biomarkers in type 2 cytokine-mediated cific IgE antibodies and their associ-
asthma management. Clin Exp Allergy. ation with asthma: A cross-section-
2017 Feb;47(2):148-60. al analysis within a population-based
18. Syabbalo N. Biomarkers for Diagnosis birth cohort. PLoSMed. 2018 Nov
and Management of Eosinophilic Asth- 13;15(11):e1002691. doi: 10.1371/jour-
ma. Ann Clin Med Res. 2020;1(1):1003. nal.pmed.1002691.
19. Li W., Gao P, Zhi Y, et al. Perios- 28. Mayo Clinic Laboratories. TEST ID:
tin: Its role in asthma and its poten- IGE [Internet]. [place unknown]: Mayo
